Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients

Gasquet, Isabelle; Gury, C.; Tcherny-Lessenot, Stéphanie; Quesnot, Ariane; Gaudebout, Pierre

doi:10.1002/pds.1122

Cited by 15 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not the case for other SGAs that clearly have a higher predilection for all drug-induced movement disorders than clozapine. There are several problems, with many of the incidence studies involving SGAs showing dramatic decreases and others showing similar rates including the use of relatively short-term study durations and hence drug exposures, comparisons with high-dose haloperidol treatment as the "gold standard", and the fact that most patients were previously exposed to, or continue to be treated with, firstgeneration agents [2,42].…”

Section: Is Td Disappearing?mentioning

confidence: 99%

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

2014

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a serious, often disabling, movement disorder that is caused by medications that block dopamine receptors (i.e., neuroleptics, anti-emetics). There is currently no standard treatment approach for physicians confronted with such patients. This may be the result of notions that TD is disappearing because of the switch to secondgeneration antipsychotic agents and that it is largely reversible.In this article we demonstrate that second-generation antipsychotics do, indeed, cause TD and, in fact, the frequency is likely higher than expected because of growing off-label uses and a tripling of prescriptions written in the last 10 years. In addition, studies demonstrate that TD actually remits in only a minority of patients when these drugs are withdrawn. Furthermore, neuroleptic agents are often utilized to treat TD, despite prolonged exposure being a risk factor for irreversibility. The outcome of these trends is a growing population afflicted with TD. We review non-neuroleptic agents that have shown positive results in small, early-phase, blinded trials, including tetrabenazine, amantadine, levetiracetam, piracetam, clonazepam, propranolol, vitamin B6, and Ginkgo biloba. Other options, such as botulinum toxin and deep brain stimulation, will also be discussed, and a suggested treatment algorithm is provided. While these agents are reasonable treatment options at this time there is a need, with a concerted effort between neurology and psychiatry, for full-scale drug development, including multicenter, randomized, blinded trials to confirm the effectiveness of the agents that were positive in phase 2 trials and the development of newer ones.

show abstract

Section: Is Td Disappearing?mentioning

confidence: 99%

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

2014

View full text Add to dashboard Cite

show abstract

“…Relevance to current prescription pattern These data, dating from a period where atypical antipsychotic prescription had not reached its present levels, 28,29 are still relevant today. First, demographical and clinical factors should be stable across time, as no dramatic change occurred in the mental health system, and this study provides valuable information on how (if at all) these factors influence prescription patterns.…”

Section: Inertia or High Prevalence Of Chemo-resistance?mentioning

confidence: 99%

“…Furthermore, it has been shown that atypical anti-psychotics have a strong impact on doses (standard or low doses more frequently prescribed compared to typical anti-psychotics). 28 Therefore, the tendency observed of higher dosage for typical and lower dosage for atypical anti-psychotics is probably still true and even accelerating. Another result requiring confirmation is the seemingly increasing weight of atypical anti-psychotics in anti-psychotic combinations (coefficient increasing from 0.30 to 0.45 between 1993 and 1999).…”

Section: Inertia or High Prevalence Of Chemo-resistance?mentioning

confidence: 99%

Predictive factors of the number and the dose of anti‐psychotics in a cohort of schizophrenic patients

Lukasiewicz

Gasquet

Casadebaig

et al. 2005

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…Due to the high prevalence of depressive disorder, the antidepressant drugs have become one of the most common medications in western countries, with as an example of 6% of users in France [19]. However, only a small proportion of MDD patients receive adequate treatment, with only one third reported a complete remission after trial of a first antidepressant followed by progressively lower response rates with each subsequent antidepressant trial [20].…”

Section: Introductionmentioning

confidence: 99%

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Haddjeri¹

2014

AAD

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is a common illness worldwide with severe socioeconomic consequences. Several hypotheses have been formulated to explain the physiopathology of depression as well as the mechanism of action of antidepressants but two of them had attracted much attention. The dominant monoaminergic hypothesis of depression links the physiopathology of MDD to a deficiency on cerebral serotonin (5-HT) and/or Norepinephrine (NE) levels; however, the relatively new neurogenic and neurotrophic hypothesis raises the possibility of an impaired neuroplasticity and/or depletion of neurotrophic factors in specific networks resulting on their structural deformity and functional impairment. An enormous body of evidence reported particular neuroadaptations following chronic administration of antidepressant drugs. In this review, we describe major adaptive changes in pre-and post-synaptic 5-HT neurotransmission as well as alterations in gene transcription and neurotrophic factors in response to long-term treatment with conventional antidepressants, new putative ones or novel promising drug candidates, all acting via 5-HT system.

show abstract

Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients

Abstract: Haloperidol was prescribed to a minority and targeted male patients hospitalized under constraint, using high dosages. Type and rate of co-prescriptions varied considerably between haloperidol and atypicals.

Cited by 15 publications

References 33 publications

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

Predictive factors of the number and the dose of anti‐psychotics in a cohort of schizophrenic patients

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Contact Info

Product

Resources

About